Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(7):469-470; doi:10.1093/jnci/94.7.469
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lotan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotan, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 7, 469-470, April 3, 2002
© 2002 Oxford University Press

EDITORIAL

Is TIG1 a New Tumor Suppressor in Prostate Cancer?

Reuben Lotan

Correspondence to: Reuben Lotan, Ph.D., Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: rlotan@mdanderson.org).

Carcinogenesis is a multistep process during which normal cells undergo a series of genetic and phenotypic changes that lead to immortalization, transformation, acquisition of tumorigenic properties, and eventually to metastatic propensity. Carcinogenesis involves the inactivation or inhibition of genes that function as tumor suppressors and the activation of genes that function as oncogenes (1). Changes in the expression and function of a variety of genes result from deletions, mutations, or epigenetic activation or silencing of transcription, and the changes in protein levels that follow or result from post-transcriptional modifications can lead to altered growth, differentiation, and apoptosis rates. Identification of the molecules and mechanisms involved in carcinogenesis holds promise for improved diagnosis and prognosis and for targeted approaches to cancer prevention and therapy.

The advent of novel molecular analyses, such as differential display . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. K. Zorn, T. Bonome, L. Gangi, G. V.R. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd, and M. J. Birrer
Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6422 - 6430.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P.-L. So, K. Lee, J. Hebert, P. Walker, Y. Lu, J. Hwang, L. Kopelovich, M. Athar, D. Bickers, M. Aszterbaum, et al.
Topical Tazarotene Chemoprevention Reduces Basal Cell Carcinoma Number and Size in Ptch1+/- Mice Exposed to Ultraviolet or Ionizing Radiation
Cancer Res., July 1, 2004; 64(13): 4385 - 4389.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y. Tokumaru, D.-I. Sun, S. Nomoto, K. Yamashita, and D. Sidransky
Re: Is TIG1 a New Tumor Suppressor in Prostate Cancer?
J Natl Cancer Inst, June 18, 2003; 95(12): 919 - 920.
[Full Text] [PDF]